

INFORME DE BÚSQUEDA Y SÍNTESIS DE COSTO-EFECTIVIDAD

Guía de Práctica Clínica Enfermedad Pulmonar Obstructiva Crónica 2019

EN PERSONAS CON EPOC CON EXACERBACIONES RECURRENTE ¿SE DEBE USAR TRIPLE TERAPIA (LABA + LAMA + CORTICOIDES) EN COMPARACIÓN A TERAPIA DUAL (LABA + LAMA)?

Uno de los factores a considerar para formular una recomendación en Guías de Práctica Clínica con la metodología “*Grading of Recommendations Assessment, Development and Evaluation*” es la relación entre la efectividad y los costos de las intervenciones a evaluar.

BÚSQUEDA DE EVALUACIONES ECONÓMICAS

La búsqueda consideró estudios de costo-efectividad y revisiones sistemáticas de evaluaciones de costo-efectividad de debe usar triple terapia (LABA+LAMA+corticoides) versus a usar a terapia dual (LABA + LAMA), en personas con enfermedad pulmonar obstructiva crónica (EPOC) con exacerbaciones recurrentes. Se identificaron términos MESH y términos de texto libre asociados a la población. La búsqueda consideró estudios publicados en inglés y español, en las siguientes bases de datos: MEDLINE, EMBASE, COCHRANE, GOOGLE, BRISA y en el National Institute for health and Care Excellence (NICE).

Ver detalle en Anexo 1 “*Términos de Búsqueda y Resultados de la búsqueda*”.

SÍNTESIS DE EVIDENCIA SEGÚN PREGUNTA

Una vez ejecutada la búsqueda, se evaluaron los títulos y resúmenes de los estudios encontrados y se seleccionaron las evaluaciones económicas que utilizaran como método la costó-utilidad y costo-efectividad.

La búsqueda entregó como resultado 93 artículos, los cuales fueron eliminados por título y abstract por no responder a la pregunta de investigación formulada para enfermedad pulmonar obstructiva crónica (EPOC).

ANEXO 1: ESTRATEGIA DE BÚSQUEDA Y RESULTADOS DE LA BÚSQUEDA

	Términos libres	DECS	MeSH
P	personas con enfermedad pulmonar obstructiva crónica (EPOC) con exacerbaciones recurrentes.	Pulmonary Disease, Chronic Obstructive OR (Airflow Obstruction, Chronic Airflow Obstructions, Chronic COAD COPD Chronic Airflow Obstruction Chronic Airflow Obstructions Chronic Obstructive Airway Disease Chronic Obstructive Lung Disease Chronic Obstructive Pulmonary Disease)	"pulmonary disease, chronic obstructive"[MeSH Terms]
I	Triple terapia (LABA+LAMA+corticoides)		
C	Terapia dual (LABA + LAMA)		
O	Cost, economic, cost-effective, cost-effectiveness, cost-benefit, health outcome, health technology assessment	Cost-Benefit Analysis	"Cost-Benefit Analysis"[Mesh])

Base de datos	Fecha de búsqueda	Resultados	Resultados después de remover duplicados
Medline-Pubmed	27-11-2019	24	24
EMBASE	27-11-2019	18	18
NICE	28-11-2019	19	19
BRISA (RedETSA)	28-11-2019	12	12
COCHRANE	29-11-2019	14	14
Google scholar	29-11-2019	6	6
Eliminados por título y resúmenes			93
Total, lectura texto completo			0
Total			0

ESTRATEGIAS DE BÚSQUEDA

PUBMED:

Estrategia	
#1	(((((chronic* AND obstructive* AND (pulmonary* OR lung* OR airway*) AND disease*) OR emphysema* OR "obstructive lung disease" OR (chronic* AND airflow* AND (obstruction* OR limitation*)) OR (hypercapni* AND respiratory* AND failure*) OR ae copd) AND (LAMA OR LABA) AND ("cost-effectiveness" OR "cost effectiveness" OR "cost-utility" OR "cost utility" OR cost minimi* OR "Cost-Benefit Analysis")))) AND model

EMBASE:

Estrategia	
1	(chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
2	(emphysema* or "obstructive lung disease").mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
3	(chronic* and airflow* and (obstruction* or limitation*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
4	(hypercapni* and respiratory* and failure*).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
5	chronic obstructive lung disease/ or aecopd.mp.
6	1 or 2 or 3 or 4 or 5
7	((long* and (((b2* or beta2* or "beta 2" or "beta-2") and (agonist* or stimulant*)) or "beta 2-agonists" or "B2-agonists" or "beta 2-agonist" or "B2-agonist")) or laba or labas).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
8	((long* and (muscarinic* or anticholinergic* or antimuscarinic*)) or lama or lamas).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
9	7 and 8

10	("LAMA" or "LABA").mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word, candidate term word]
11	9 and 10
12	6 and 11
13	("cost-effectiveness" or "cost effectiveness" or "cost-utility" or "cost utility" or cost minimi\$).ti,ab.
14	12 and 13
15	limit 14 to conference abstract status
16	14 not 15

NICE

Estrategia
("cost effectiveness" or "cost effectiveness" or "cost utility" or "cost utility" or cost minimi*) AND (chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*) AND LABA AND LAMA

BRISA:

Estrategia
enfermedad pulmonar obstructiva crónica

COCHRANE

ID	Search
#1	(cost-effectiveness or "cost effectiveness" or cos-utility analysis or "cost-utility analysis" or cost-benefit analysis or "cost-benefit analysis" or "cost effectiveness analysis")
#2	(chronic* and obstructive* and (pulmonary* or lung* or airway*) and disease*)
#3	LABA OR LAMA
#4	#1 AND #2
#5	#3 AND #4
#6	Model:ab
#7	QALY:ab
#8	#6 AND #7
#9	#5 AND #8

Google Scholar

ID	Search
#1	(allintitle: (cost-effectiveness OR "cost effectiveness" OR "economic evaluation") AND (severe chronic obstructive pulmonary disease) AND (LABA OR LAMA)

2	(allintitle: (cost-effectiveness OR "cost effectiveness" OR "economic evaluation") AND (enfermedad pulmonar obstructiva crónica) AND (LABA OR LAMA)
3	cost-effectiveness OR "cost effectiveness" OR "economic evaluation") AND (severe chronic obstructive pulmonary disease) AND (LABA OR LAMA)